ArticleChinese medicine2026
TCMNet: an AI-driven strategy for optimizing traditional Chinese medicine.
Article in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundArtificial intelligence (AI), particularly large language models (LLMs), have provided powerful tools for systematically modeling the complexity of traditional Chinese medicine (TCM). To overcome the limitations of subjective formula design and unweighted target prioritization, we developed TCMNet, an AI-powered strategy that integrates LLM-assisted disease knowledge mining, protein-protein interaction (PPI) networks, and deep learning-based binding prediction to support herbal formula evaluation and active compounds identification.
methodsTCMNet integrates AI-guided literature analysis with weighted PPI network evaluation. Parkinson's disease (PD) was chosen as the representative case study. Disease-associated protein targets were semantically weighted using TCMChat, a TCM-specific LLM that extracts relevant targets from Chinese and English literature. Furthermore, herb-specific information data, such as composition ratios, compound abundance, and compound-protein interaction probabilities, was used to generate weighted herb-related proteins. These weights were incorporated into a PPI network to assign biological weight to each node. Four classical TCM formulas (Tianma Gouteng Decoction, Liuwei Dihuang, Qianzheng San, Dabuyin Wan), the clinically optimized Pingchan Granule (PCG), and their integrative combinations with Western medicine (Levodopa) were systematically evaluated alongside the single-herb Ginkgo biloba. Therapeutic relevance was assessed using network-based metrics such as target coverage, Jaccard similarity, and weighted proximity, with statistical significance measured by Z-scores. To validate key active compounds, we employed Boltz-2, a state-of-the-art deep learning method, to predict the binding probabilities between herbal compounds and prioritized PD-associated proteins.
resultsWeighted proximity metrics markedly outperformed unweighted measures across all four evaluated TCM formulas, demonstrating the substantial benefit of integrating node weights. Among the evaluated formulas, Tianma Gouteng Decoction demonstrated superior performance in target coverage and network proximity, aligning well with existing literature. Computational validation on Pingchan Granule (PCG) confirmed that TCMNet successfully captures the therapeutic retention of formula optimization. Furthermore, integrative strategies combining TCM with Levodopa exhibited significantly enhanced network proximity compared to monotherapy, supporting the rationale for combined treatment. Moreover, the case study identified flavonoids and isoflavonoids from Ginkgo biloba as the primary bioactive constituents contributing to anti-PD activity. Boltz-2 deep learning predictions further confirmed that flavonoid compounds exhibited significantly higher binding probabilities and affinities toward key PD-associated proteins compared to non-flavonoids, thus validating the results of TCMNet.
conclusionsBy explicitly incorporating protein weights through combining LLM-guided target identification with node-weighted evaluation, TCMNet offers a new AI-driven strategy for optimizing TCM. This approach enables herbal formula evaluation and optimization as well as the identification of bioactive constituents, advancing the modernization of herbal medicine research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.